UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/557,823	02/13/2007	Pia Daniel	P70915US0	6057
	7590 08/27/200 OLMAN PLLC	EXAMINER		
400 SEVENTH STREET N.W.			CHRISTIAN, MARJORIE ELLEN	
SUITE 600 WASHINGTON, DC 20004			ART UNIT	PAPER NUMBER
			1797	
			MAIL DATE	DELIVERY MODE
			08/27/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/557,823	DANIEL, PIA
Office Action Summary	Examiner	Art Unit
	MARJORIE CHRISTIAN	1797
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tind will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 23 I	s action is non-final. ance except for formal matters, pro	
Disposition of Claims		
4) Claim(s) 1-15 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) 1-15 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	awn from consideration. or election requirement.	
10) The drawing(s) filed on is/are: a) acceptable and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct should be contained as a contained to by the E	cepted or b) objected to by the I drawing(s) be held in abeyance. See ction is required if the drawing(s) is objection	e 37 CFR 1.85(a). lected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat* * See the attached detailed Office action for a list	nts have been received. nts have been received in Applicationity documents have been received au (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate

Art Unit: 1797

DETAILED ACTION

Summary

This is the initial Office action based on the application filed November 25th,
 2005.

2. Claims 1-15 are pending and have been fully considered.

Priority

3. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

4. <u>Claims 1-3, 5-6, 10-15</u> are rejected under 35 U.S.C. 102(b) as being anticipated by US PGPub 2003/0135152, KOLLAR et al..

As to **Claim 1**, KOLLAR discloses blood treatment equipment (Abstract, Ref. 1, specifically see Figs. 1, 2A, 2B) comprising: a blood treatment device (112) which is part of an extracorporeal blood circulatory system (Fig. 2A, B) with actuators (31-36, 46, 98-99, 401-405) controlled by a control unit (10, 300, 306, 304, 312), the control unit comprises a display and input unit (50) with a touch screen (54, 55), wherein the display

Page 3

and input unit (50) comprises various mode means (for example 260b', 260b'', Pg. 21, Para. 235-236) that show various time modes of a blood treatment on the touch screen (54,55) wherein the mode means (Fig. 27, 30, 33) are selectable by an operator via the touch screen; the control unit identifies the running time mode and instructs the display and input unit to show the mode means selected from the other mode means using different symbols and establishes the end of one time mode and automatically initiates the beginning of the next and communicates this to the display and input unit, changing the representation of the selected mode means (Pg. 16, Para. 175; Pg. 17, Para. 181-182; Pg. 20, Para. 221).

As to **Claim 2**, KOLLAR discloses that the mode means are arranged with respect to one another in their time sequence (Pg. 20, Para. 221).

As to **Claim 3**, KOLLAR discloses that the mode means comprise blood treatment preparation means, blood treatment means and blood treatment after-preparation means (Ref. 242, Pg. 20, Para. 220).

As to **Claims 5-6**, KOLLAR discloses that the mode means (242) are represented in the form of a cell at one edge of the touch screen (upper left corner of Figs. 30A-L) and the remaining area of the touch screen represents further input means depending on the time mode (see rest of display in Figs. 30A-L).

As to **Claim 10**, KOLLAR discloses that the control unit (10, 300, 306, 304, 312) instructs the display and input unit (50) to display a check mark when the steps have been completed (Pg. 21, Para. 236) [third type of symbol], where it is implicit that its input function is deactivated if the step is completed.

Art Unit: 1797

As to **Claim 11**, KOLLAR discloses that the display and input unit (50) displays the mode means (242) in all time modes at the same point of the touch screen (Figs. 30A-L).

As to **Claims 12-14**, KOLLAR discloses that the blood treatment equipment comprises blood detectors and air detectors, and the control unit evaluates the values of the sensors to determine the end of a time mode and the presence of correctly mounted components (Para. 47, 330, Figs. 33).

As to **Claim 15**, KOLLAR discloses that the control unit determines the quantity of fluid conveyed by a controlled pump (6, 22, 23) to determine the end of a time mode. (Para. 53, 397)

5. <u>Claims 1, 5-9, 12-13, 15</u> are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,247,434, PETERSON et al..

As to Claims 1, 7, PETERSEN discloses an hemodialysis apparatus controlled by a control unit with a touch screen (Abstract) comprising: a blood treatment device (Fig. 1) which is part of an extracorporeal blood circulatory system with actuators (12, 14, 22, 24, 42, 50, 54, 56) controlled by a control unit (Fig. 7, C8/L36-41, examples include C13/L55-64 Blood Pump System, C16/L45-60 UF Control System), the control unit comprises a display and input unit (Fig. 8-11) with a touch screen (C8/L19-20) and various mode means that are selectable by an operator via the touch screen; the control unit identifies the running time mode and displays the selected mode using different symbols from the other modes and establishes the end of one time mode and

Art Unit: 1797

automatically initiates the beginning of the next one, this is communicated to the display and input unit, changing the representation of the selected mode means (C11/L8-43).

Page 5

As to Claim 2, KOLLAR discloses that the mode means are arranged with respect to one another in their time sequence (Figs. 8-11).

As to **Claim 3**, KOLLAR discloses that the mode means comprise blood treatment preparation means, blood treatment means and blood treatment after-preparation means (C13/L9-21, C32/L29-50, C35/L3-18).

As to **Claims 5-6**, KOLLAR discloses that the mode means (i.e. Menus) are represented in the form of a cell at one edge of the touch screen (right side of Figs. 8-11) and the remaining area of the touch screen represents further input means depending on the time mode (see rest of display in Figs. 8-11).

As to **Claim 8**, PETERSON discloses that the blood treatment preparation means comprises a rinse mode, self-test mode and prime mode (C11/L28-29) [blood system mode and preparation mode].

As to Claim 9, PETERSON discloses that the blood after-preparation means comprises modes for re-infusion (C35/L3-18) and purification (C32/L29-50).

As to Claims 12-13, 15, KOLLAR discloses that the blood treatment equipment comprises blood detectors and air detectors, and the control unit evaluates the values of the sensors to determine the end of a time mode (C13/L5-17, C20/L40-50); and determines the quantity of fluid conveyed by a controlled pump to determine the end of a time mode (C16/L45-60, Fig. 11, see also UF Removal Control (Col. 18)).

Art Unit: 1797

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 6. <u>Claim 4</u> is rejected under 35 USC 103 (a) as being obvious over US PGPub 2003/0135152, KOLLAR et al..

As to Claim 4, KOLLAR discloses the mode means display (242) on the touch screens (Fig. 30A-L), but does not appear to expressly disclose that the blood treatment means on the touch screen has a larger area than the other mode means. However, the size of the blood treatment means on the touch screen presents no novel or unexpected result over the reference and would be an obvious matter of design choice within the skill of the art. In re Launder, 42 CCPA 886, 222 F.2d 371, 105 USPQ 446 (1955); Flour City Architectural Metals v. Alpana Aluminum Products, Inc., 454 F. 2d 98, 172 USPQ 341 (8th Cir. 1972); National Connector Corp. v. Malco Manufacturing Co., 392 F.2d 766. 157 USPQ 401 (8th Cir.) cert. denied, 393 U.S. 923, 159 USPQ 799

Art Unit: 1797

(1968). Further it has been held that changes in configuration are a matter of design choice. *In re Dailey, 357 F.2d 669, 149 USPQ 47 (CCPA 1966).* Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Conclusion

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARJORIE CHRISTIAN whose telephone number is (571)270-5544. The examiner can normally be reached on Monday through Thursday 7-5pm (Fridays off).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vickie Kim can be reached on (571)272-0579. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Art Unit: 1797

/Krishnan S Menon/ Primary Examiner, Art Unit 1797

МС